Sanofi and Orana Med’s radiopharmaceutical candidate has met all its primary endpoints in a Phase II trial, meaning the former’s €320m bet on the therapy looks to be paying off. In the ongoing ...
When Is Enough Enough? Personalized Decision Making in Long-Term Cancer Care This review aims to understand the perspectives of patients with well-differentiated GEP-NETs on considering radioligand ...
Garching / Munich, April 21, 2026 –– ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide quality of life data from its Phase 3 ...
Retreatment patterns and outcomes in patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE): A PRIME real-world study. Clinical ...
The COMPETE trial (NCT03049189) evaluated (177) Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results